Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Generic Drugs Office Faces Transition As Director Buehler Departs

Executive Summary

FDA's Office of Generic Drugs is poised to enter a new era with new leadership, even as the agency is saying it will draw on the expertise of veteran officials for key initiatives
Advertisement

Related Content

GDUFA II: FDA Prefers A ‘Manageable Number of High-Impact Changes’
FDA Generics Office To Be Managed By Relative Unknown
Growing Pains for Generic Drugs: OGD Gains Respect, But Loses Geba
FDA Generics Director’s Departure Shows Why Chemistry Matters
FDA’s Generics Office Loses Another Director As Geba Makes Quick Exit
GPhA Seeks New Driver As Outgoing VP Johnston Continues To Ford Across User Fee Stream
ANDA User Fees: Industry Takes Holistic Approach, Wants Whole New Office
ANDA User Fees: Industry Takes Holistic Approach, Wants Whole New Office
For Watson CEO Bisaro, “Operational Efficiency” Is An Industry-Wide Calling
FDA Review Of Follow-On Biologics Would Put Brands, Generics Under One Roof

Topics

Advertisement
UsernamePublicRestriction

Register

PS052008

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel